HC Wainwright Brokers Raise Earnings Estimates for RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous forecast of ($0.81). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($2.79) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). The business had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer began coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They set an “outperform” rating and a $76.00 target price for the company. Stifel Nicolaus began coverage on Rhythm Pharmaceuticals in a research note on Wednesday. They set a “buy” rating and a $78.00 target price for the company. Canaccord Genuity Group boosted their target price on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 27th. Finally, Jefferies Financial Group began coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a “buy” rating and a $80.00 target price for the company. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $69.08.

Rhythm Pharmaceuticals Stock Performance

Shares of Rhythm Pharmaceuticals stock opened at $51.64 on Thursday. Rhythm Pharmaceuticals has a one year low of $35.17 and a one year high of $68.58. The company has a market cap of $3.17 billion, a PE ratio of -11.93 and a beta of 2.30. The business has a 50-day simple moving average of $56.73 and a 200-day simple moving average of $54.47.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. SRS Capital Advisors Inc. raised its position in Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after acquiring an additional 400 shares in the last quarter. Raleigh Capital Management Inc. purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth $28,000. SBI Securities Co. Ltd. purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth $37,000. R Squared Ltd purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth $44,000. Finally, State of Wyoming purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth $61,000.

Insider Buying and Selling

In related news, insider Joseph Shulman sold 794 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $57.51, for a total transaction of $45,662.94. Following the completion of the sale, the insider now directly owns 6 shares of the company’s stock, valued at $345.06. This trade represents a 99.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Christopher Paul German sold 635 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the transaction, the chief accounting officer now owns 2,070 shares of the company’s stock, valued at $118,445.40. The trade was a 23.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,787 shares of company stock valued at $1,901,443 over the last three months. 5.60% of the stock is currently owned by company insiders.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.